Patients With Rheumatoid Arthritis (RA) Treated With Rituximab in Kuopio University Hospital (KuoRituxi1)
One centre follow-up study on safety and efficacy of treatment with rituximab among patients with RA during 4 year period. Basic data is collected for the national register of biologicals.
Drug: rituximab, observational study amon patients with active RA
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
|Official Title:||One Centre Follow-up Study on Safety and Efficacy|
- ACR20 ACR50 ACR70 response [ Time Frame: 6 and 12 months ] [ Designated as safety issue: No ]
- Duration of clinical response [ Time Frame: 6 and 12 months ] [ Designated as safety issue: No ]
|Study Start Date:||November 2004|
|Study Completion Date:||July 2008|
|Primary Completion Date:||July 2008 (Final data collection date for primary outcome measure)|
patients with active RA
rituximab two 1000 mg intravenous infusions separated by two weeksDrug: rituximab, observational study amon patients with active RA
two 1000 mg intravenous infusions separated by 2 weeks
Data is collected on regular visits in the outpatient department. In collection national register forms have been used.